Pharmaceutical Products Companies By Ebitda
LargestBiggest EarnersMost ProfitableMost LiquidHighly LeveragedTop DividendsCapital-HeavyHighest ValuationLargest Workforce
EBITDA
| EBITDA | Efficiency | Market Risk | Exp Return | ||||
|---|---|---|---|---|---|---|---|
| 1 | VRTX | Vertex Pharmaceuticals | (0.05) | 1.72 | (0.09) | ||
| 2 | VTRS | Viatris | 0.10 | 2.26 | 0.22 | ||
| 3 | NWBO | Northwest Biotherapeutics | (0.09) | 3.45 | (0.30) | ||
| 4 | VYGR | Voyager Therapeutics | (0.04) | 4.92 | (0.18) | ||
| 5 | TLX | Telix Pharmaceuticals Limited | (0.23) | 1.57 | (0.37) | ||
| 6 | XOMAP | XOMA Corp | 0.07 | 0.76 | 0.05 | ||
| 7 | XOMAO | XOMA Corporation | 0.10 | 0.40 | 0.04 | ||
| 8 | DVAX | Dynavax Technologies | 0.07 | 2.46 | 0.16 | ||
| 9 | SNYR | SYNERGY CHC P | 0.29 | 266.54 | 78.57 | ||
| 10 | VCEL | Vericel Corp Ord | 0.10 | 3.08 | 0.31 | ||
| 11 | DRMA | Dermata Therapeutics | (0.04) | 8.35 | (0.30) | ||
| 12 | TVGNW | Tevogen Bio Holdings | 0.18 | 25.94 | 4.65 | ||
| 13 | CDTTW | Conduit Pharmaceuticals | 0.10 | 29.98 | 3.01 | ||
| 14 | GELS | Gelteq Limited Ordinary | (0.20) | 9.40 | (1.87) | ||
| 15 | CDIOW | Cardio Diagnostics Holdings | 0.13 | 136.66 | 17.62 | ||
| 16 | VRPX | Virpax Pharmaceuticals | (0.04) | 7.07 | (0.30) | ||
| 17 | CEROW | CERo Therapeutics Holdings | 0.15 | 37.94 | 5.59 | ||
| 18 | ELAB | Elevai Labs, Common | (0.18) | 15.30 | (2.74) | ||
| 19 | VRAX | Virax Biolabs Group | (0.10) | 9.18 | (0.90) | ||
| 20 | DRUG | Bright Minds Biosciences | 0.14 | 125.82 | 17.76 |
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital. In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.